期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 77, 期 5, 页码 620-628出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.11.056
关键词
monacolin K; nutraceutical; red yeast rice; safety
资金
- Meda-Mylan
- Sharper
- Meda
The extracts of red yeast rice are the most effective cholesterol-lowering nutraceuticals currently available, reducing LDL-cholesterol levels and potentially improving cardiovascular health, endothelial function, and preventing cardiovascular events.
The extracts of red yeast rice (RYR) are currently the most effective cholesterol-lowering nutraceuticals. This activity is mainly due to monacolin K, a weak reversible inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, whose daily consumption causes a reduction in low-density lipoprotein (LDL)-cholesterol plasma levels up to 15% to 25% within 6 to 8 weeks. The decrease in LDL-cholesterol is accompanied by a proportional decrease in total and non-high-density lipoprotein cholesterol, plasma apolipoprotein B, and high-sensitivity C-reactive protein. Some trials suggest that RYR use is associated with improvement in endothelial function and arterial stiffness, whereas a long-term study supports its role in the prevention of cardiovascular events. Despite the statin-like mechanism of action, the risk related to 3 to 10 mg monacolin K taken per day is minimal (mild myalgia in previously severely statin-intolerant subjects). RYR could represent a therapeutic tool to support lifestyle improvement in managing mild to moderate hypercholesterolemia in low-risk patients, including those who cannot be treated with statins or other LDL-cholesterol-lowering therapies. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据